Compare BridgeBio Pharma Inc (BBIO) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Phillips 66 — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Phillips 66 trades at $224.35 (market cap $86.00B). The key difference: Phillips 66 is far larger — about 5.2× BridgeBio Pharma Inc's market cap, and Phillips 66 pays a 2.36% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | PSX | |
|---|---|---|
Market Cap | $16.61B | $86.00B |
Sector | Health | Energy |
52-Week High | $90.17 | $215.52 |
52-Week Low | $47.29 | $118.37 |
Enterprise Value | $18.16B | $102.46B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Phillips 66 (PSX) trades at $203.91, down 0.78% on the day, with a bearish technical signal but strong fundamental tailwinds from refining margins. Recent Q2 2026 earnings of $9.41 per share beat estimates, driven by high utilization and robust cash flow. The stock has support near $201 and resistance at $206, with a consensus price target of $221.92 suggesting upside potential.
Outlook is positive due to sustained refining profitability and debt reduction, but risks include volatile crude prices and geopolitical tensions. Analysts are predominantly bullish (57% buy ratings), though technical indicators warn of near-term pressure. Investors should weigh strong fundamentals against sector cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
